<DOC>
	<DOC>NCT00581555</DOC>
	<brief_summary>The purpose of this study is to evaluate the use of etanercept as a replacement therapy for ciclosporin in patients with plaque psoriasis.</brief_summary>
	<brief_title>Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy</brief_title>
	<detailed_description>The purpose of this study is to evaluate the efficacy and safety of etanercept as a replacement therapy for ciclosporin in patients with moderate to severe plaque psoriasis who have achieved an adequate response with ciclosporin.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Between age 18 and 70 years Active and stable plaque psoriasis with a BSA≥10 or PASI≥10. Evidence of skin conditions other than psoriasis Psoralen plus psoralen + ultraviolet A (PUVA), ciclosporin, acitretin, alefacept, anakinra, or any other systemic antipsoriasis therapy or diseasemodifying antirheumatic drugs (DMARD) with 28 days of screening ultraviolet B (UVB) therapy, topical steroids, topical Vitamin A or D analog preparations, or anthralin Prior exposure to any TNFinhibitor. Prior exposure to efalizumab Corticosteroid dose of prednisone &gt;10 mg/day Serious infection Receipt of any live vaccine Abnormal hematology or chemistry Body mass index (BMI) &gt; 38 Pregnancy or Breastfeeding Significant concurrent medical conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>